N6-Methyladenosine methylation modification in breast cancer: current insights.
N6-Methyladenosine (m6A)
Breast cancer
Methylation modification
Prognosis
m6A regulators
Journal
Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741
Informations de publication
Date de publication:
28 Oct 2024
28 Oct 2024
Historique:
received:
11
08
2024
accepted:
16
10
2024
medline:
29
10
2024
pubmed:
29
10
2024
entrez:
29
10
2024
Statut:
epublish
Résumé
Breast cancer is the most common cancer type among women. Despite advanced treatment strategies, some patients still face challenges in disease control, prompting the exploration of new therapeutic approaches. N6-Methyladenosine (m6A) methylation modification regulates RNA and plays a crucial role in various tumor biological processes, closely linked to breast cancer occurrence, development, prognosis, and treatment. M6A regulators impact breast cancer progression, development, and drug resistance by modulating RNA metabolism and tumor-related pathways. Researchers have begun to understand the regulatory mechanisms of m6A methylation in breast cancer. This paper discusses the roles of m6A regulators in breast cancer progression, prognosis, and treatment, offering new perspectives for breast cancer diagnosis and treatment.
Identifiants
pubmed: 39468547
doi: 10.1186/s12967-024-05771-x
pii: 10.1186/s12967-024-05771-x
doi:
Substances chimiques
Adenosine
K72T3FS567
N-methyladenosine
CLE6G00625
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
971Subventions
Organisme : Natural Science Foundation of Shanxi Province
ID : 202203021221250
Informations de copyright
© 2024. The Author(s).
Références
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024. https://doi.org/10.3322/caac.21834 .
doi: 10.3322/caac.21834
pubmed: 38572751
Abrahão CA, Bomfim E, Lopes-Júnior LC, Pereira-da-Silva G. Complementary therapies as a strategy to reduce stress and stimulate immunity of women with breast cancer. J Evid Based Integr Med. 2019;24:2515690x19834169. https://doi.org/10.1177/2515690x19834169 .
doi: 10.1177/2515690x19834169
pubmed: 30917682
pmcid: 6440038
Rachdi H, Mokrani A, Batti R, Ayadi M, Chraiet N, Mezlini A. Target therapy for metastatic breast cancer. Tunis Med. 2018;96(8–9):465–71.
pubmed: 30430522
Zhang B, Wu Q, Li B, Wang D, Wang L, Zhou YL. m(6)A regulator-mediated methylation modification patterns and tumor microenvironment infiltration characterization in gastric cancer. Mol Cancer. 2020;19(1):53. https://doi.org/10.1186/s12943-020-01170-0 .
doi: 10.1186/s12943-020-01170-0
pubmed: 32164750
pmcid: 7066851
Mobet Y, Liu X, Liu T, Yu J, Yi P. Interplay between m(6)A RNA methylation and regulation of metabolism in cancer. Front Cell Dev Biol. 2022;10: 813581. https://doi.org/10.3389/fcell.2022.813581 .
doi: 10.3389/fcell.2022.813581
pubmed: 35186927
pmcid: 8851358
Chen H, Gao S, Liu W, et al. RNA N(6)-methyladenosine methyltransferase METTL3 facilitates colorectal cancer by activating the m(6)A-GLUT1–mTORC1 axis and is a therapeutic target. Gastroenterology. 2021;160(4):1284-1300.e16. https://doi.org/10.1053/j.gastro.2020.11.013 .
doi: 10.1053/j.gastro.2020.11.013
pubmed: 33217448
Shen R. Commentary on metabolic reprogramming-associated genes predict overall survival for rectal cancer. J Cell Mol Med. 2020;24(21):12862–3. https://doi.org/10.1111/jcmm.15938 .
doi: 10.1111/jcmm.15938
pubmed: 33090720
pmcid: 7686981
Liao S, Sun H, Xu C. YTH domain: a family of N(6)-methyladenosine (m(6)A) readers. Genom Proteom Bioinform. 2018;16(2):99–107. https://doi.org/10.1016/j.gpb.2018.04.002 .
doi: 10.1016/j.gpb.2018.04.002
Harper JE, Miceli SM, Roberts RJ, Manley JL. Sequence specificity of the human mRNA N6-adenosine methylase in vitro. Nucleic Acids Res. 1990;18(19):5735–41. https://doi.org/10.1093/nar/18.19.5735 .
doi: 10.1093/nar/18.19.5735
pubmed: 2216767
pmcid: 332308
Zhang Z, Theler D, Kaminska KH, et al. The YTH domain is a novel RNA binding domain. J Biol Chem. 2010;285(19):14701–10. https://doi.org/10.1074/jbc.M110.104711 .
doi: 10.1074/jbc.M110.104711
pubmed: 20167602
pmcid: 2863249
Xu C, Wang X, Liu K, et al. Structural basis for selective binding of m6A RNA by the YTHDC1 YTH domain. Nat Chem Biol. 2014;10(11):927–9. https://doi.org/10.1038/nchembio.1654 .
doi: 10.1038/nchembio.1654
pubmed: 25242552
Nachtergaele S, He C. The emerging biology of RNA post-transcriptional modifications. RNA Biol. 2017;14(2):156–63. https://doi.org/10.1080/15476286.2016.1267096 .
doi: 10.1080/15476286.2016.1267096
pubmed: 27937535
Schöller E, Weichmann F, Treiber T, et al. Interactions, localization, and phosphorylation of the m(6)A generating METTL3–METTL14–WTAP complex. RNA. 2018;24(4):499–512. https://doi.org/10.1261/rna.064063.117 .
doi: 10.1261/rna.064063.117
pubmed: 29348140
pmcid: 5855951
Wang X, Feng J, Xue Y, et al. Structural basis of N(6)-adenosine methylation by the METTL3–METTL14 complex. Nature. 2016;534(7608):575–8. https://doi.org/10.1038/nature18298 .
doi: 10.1038/nature18298
pubmed: 27281194
Liu J, Yue Y, Han D, et al. A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93–5. https://doi.org/10.1038/nchembio.1432 .
doi: 10.1038/nchembio.1432
pubmed: 24316715
Knuckles P, Lence T, Haussmann IU, et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev. 2018;32(5–6):415–29. https://doi.org/10.1101/gad.309146.117 .
doi: 10.1101/gad.309146.117
pubmed: 29535189
pmcid: 5900714
Yue Y, Liu J, Cui X, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3′UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10. https://doi.org/10.1038/s41421-018-0019-0 .
doi: 10.1038/s41421-018-0019-0
pubmed: 29507755
pmcid: 5826926
Patil DP, Chen CK, Pickering BF, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369–73. https://doi.org/10.1038/nature19342 .
doi: 10.1038/nature19342
pubmed: 27602518
pmcid: 5509218
Meyer KD, Jaffrey SR. Rethinking m(6)A readers, writers, and erasers. Annu Rev Cell Dev Biol. 2017;33:319–42. https://doi.org/10.1146/annurev-cellbio-100616-060758 .
doi: 10.1146/annurev-cellbio-100616-060758
pubmed: 28759256
pmcid: 5963928
Wei J, Liu F, Lu Z, et al. Differential m(6)A, m(6)A(m), and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 2018;71(6):973-985.e5. https://doi.org/10.1016/j.molcel.2018.08.011 .
doi: 10.1016/j.molcel.2018.08.011
pubmed: 30197295
pmcid: 6151148
Wang X, Zhao BS, Roundtree IA, et al. N(6)-Methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6):1388–99. https://doi.org/10.1016/j.cell.2015.05.014 .
doi: 10.1016/j.cell.2015.05.014
pubmed: 26046440
pmcid: 4825696
Wu B, Li L, Huang Y, Ma J, Min J. Readers, writers and erasers of N(6)-methylated adenosine modification. Curr Opin Struct Biol. 2017;47:67–76. https://doi.org/10.1016/j.sbi.2017.05.011 .
doi: 10.1016/j.sbi.2017.05.011
pubmed: 28624569
Xiang Y, Laurent B, Hsu CH, et al. RNA m(6)A methylation regulates the ultraviolet-induced DNA damage response. Nature. 2017;543(7646):573–6. https://doi.org/10.1038/nature21671 .
doi: 10.1038/nature21671
pubmed: 28297716
pmcid: 5490984
Hsu PJ, Zhu Y, Ma H, et al. Ythdc2 is an N(6)-methyladenosine binding protein that regulates mammalian spermatogenesis. Cell Res. 2017;27(9):1115–27. https://doi.org/10.1038/cr.2017.99 .
doi: 10.1038/cr.2017.99
pubmed: 28809393
pmcid: 5587856
Shi H, Wang X, Lu Z, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315–28. https://doi.org/10.1038/cr.2017.15 .
doi: 10.1038/cr.2017.15
pubmed: 28106072
pmcid: 5339834
Huang H, Weng H, Zhou K, et al. Histone H3 trimethylation at lysine 36 guides m(6)A RNA modification co-transcriptionally. Nature. 2019;567(7748):414–9. https://doi.org/10.1038/s41586-019-1016-7 .
doi: 10.1038/s41586-019-1016-7
pubmed: 30867593
pmcid: 6438714
Jiang X, Liu B, Nie Z, et al. The role of m6A modification in the biological functions and diseases. Signal Transduct Target Ther. 2021;6(1):74. https://doi.org/10.1038/s41392-020-00450-x .
doi: 10.1038/s41392-020-00450-x
pubmed: 33611339
pmcid: 7897327
Shah A, Rashid F, Awan HM, et al. The DEAD-Box RNA helicase DDX3 interacts with m(6)A RNA demethylase ALKBH5. Stem Cells Int. 2017;2017:8596135. https://doi.org/10.1155/2017/8596135 .
doi: 10.1155/2017/8596135
pubmed: 29333169
pmcid: 5733242
Youssef R, Maniar R, Khan J, Mesa H. Metabolic interplay in the tumor microenvironment: implications for immune function and anticancer response. Curr Issues Mol Biol. 2023;45(12):9753–67. https://doi.org/10.3390/cimb45120609 .
doi: 10.3390/cimb45120609
pubmed: 38132455
pmcid: 10742411
Hu J, Qiu D, Yu A, et al. YTHDF1 is a potential pan-cancer biomarker for prognosis and immunotherapy. Front Oncol. 2021;11: 607224. https://doi.org/10.3389/fonc.2021.607224 .
doi: 10.3389/fonc.2021.607224
pubmed: 34026603
pmcid: 8134747
Wan W, Ao X, Chen Q, et al. METTL3/IGF2BP3 axis inhibits tumor immune surveillance by upregulating N(6)-methyladenosine modification of PD-L1 mRNA in breast cancer. Mol Cancer. 2022;21(1):60. https://doi.org/10.1186/s12943-021-01447-y .
doi: 10.1186/s12943-021-01447-y
pubmed: 35197058
pmcid: 8864846
Dong M, Shen W, Yang G, Yang Z, Li X. Analysis of m6A methylation modification patterns and tumor immune microenvironment in breast cancer. Front Cell Dev Biol. 2022;10: 785058. https://doi.org/10.3389/fcell.2022.785058 .
doi: 10.3389/fcell.2022.785058
pubmed: 35178386
pmcid: 8846385
Zheng F, Du F, Zhao J, et al. The emerging role of RNA N6-methyladenosine methylation in breast cancer. Biomark Res. 2021;9(1):39. https://doi.org/10.1186/s40364-021-00295-8 .
doi: 10.1186/s40364-021-00295-8
pubmed: 34044876
pmcid: 8161983
Chang G, Shi L, Ye Y, et al. YTHDF3 induces the translation of m(6)A-enriched gene transcripts to promote breast cancer brain metastasis. Cancer Cell. 2020;38(6):857-871.e7. https://doi.org/10.1016/j.ccell.2020.10.004 .
doi: 10.1016/j.ccell.2020.10.004
pubmed: 33125861
pmcid: 7738369
Lin S, Choe J, Du P, Triboulet R, Gregory RI. The m(6)A methyltransferase METTL3 promotes translation in human cancer cells. Mol Cell. 2016;62(3):335–45. https://doi.org/10.1016/j.molcel.2016.03.021 .
doi: 10.1016/j.molcel.2016.03.021
pubmed: 27117702
pmcid: 4860043
Yan C, Xiong J, Zhou Z, et al. A cleaved METTL3 potentiates the METTL3–WTAP interaction and breast cancer progression. Elife. 2023. https://doi.org/10.7554/eLife.87283 .
doi: 10.7554/eLife.87283
pubmed: 38078907
pmcid: 10712958
Xu Y, Song M, Hong Z, et al. The N6-methyladenosine METTL3 regulates tumorigenesis and glycolysis by mediating m6A methylation of the tumor suppressor LATS1 in breast cancer. J Exp Clin Cancer Res. 2023;42(1):10. https://doi.org/10.1186/s13046-022-02581-1 .
doi: 10.1186/s13046-022-02581-1
pubmed: 36609396
pmcid: 9824909
Wang J, Fan P, Shen P, et al. XBP1s activates METTL3/METTL14 for ER-phagy and paclitaxel sensitivity regulation in breast cancer. Cancer Lett. 2024;596: 216846. https://doi.org/10.1016/j.canlet.2024.216846 .
doi: 10.1016/j.canlet.2024.216846
pubmed: 38582397
Ouyang D, Hong T, Fu M, et al. METTL3 depletion contributes to tumour progression and drug resistance via N6 methyladenosine-dependent mechanism in HR+HER2-breast cancer. Breast Cancer Res. 2023;25(1):19. https://doi.org/10.1186/s13058-022-01598-w .
doi: 10.1186/s13058-022-01598-w
pubmed: 36765397
pmcid: 9921123
Shi Y, Zheng C, Jin Y, et al. Reduced expression of METTL3 promotes metastasis of triple-negative breast cancer by m6A methylation-mediated COL3A1 up-regulation. Front Oncol. 2020;10:1126. https://doi.org/10.3389/fonc.2020.01126 .
doi: 10.3389/fonc.2020.01126
pubmed: 32766145
pmcid: 7381173
Chen F, Chen Z, Guan T, et al. N(6)-Methyladenosine regulates mRNA stability and translation efficiency of KRT7 to promote breast cancer lung metastasis. Cancer Res. 2021;81(11):2847–60. https://doi.org/10.1158/0008-5472.Can-20-3779 .
doi: 10.1158/0008-5472.Can-20-3779
pubmed: 33795252
Zhu XJ, Feng JQ, Zheng MZ, et al. Metal-protein nanoparticles facilitate anti-VSV and H1N1 viruses through the coordinative actions on innate immune responses and METTL14. Macromol Biosci. 2021;21(4): e2000382. https://doi.org/10.1002/mabi.202000382 .
doi: 10.1002/mabi.202000382
pubmed: 33522144
Yankova E, Blackaby W, Albertella M, et al. Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021;593(7860):597–601. https://doi.org/10.1038/s41586-021-03536-w .
doi: 10.1038/s41586-021-03536-w
pubmed: 33902106
pmcid: 7613134
Zhao C, Ling X, Xia Y, Yan B, Guan Q. LncRNA UCA1 promotes SOX12 expression in breast cancer by regulating m(6)A modification of miR-375 by METTL14 through DNA methylation. Cancer Gene Ther. 2022;29(7):1043–55. https://doi.org/10.1038/s41417-021-00390-w .
doi: 10.1038/s41417-021-00390-w
pubmed: 35022519
Yi D, Wang R, Shi X, Xu L, Yilihamu Y, Sang J. METTL14 promotes the migration and invasion of breast cancer cells by modulating N6-methyladenosine and hsa-miR-146a-5p expression. Oncol Rep. 2020;43(5):1375–86. https://doi.org/10.3892/or.2020.7515 .
doi: 10.3892/or.2020.7515
pubmed: 32323801
pmcid: 7107905
Gong PJ, Shao YC, Yang Y, et al. Analysis of N6-methyladenosine methyltransferase reveals METTL14 and ZC3H13 as tumor suppressor genes in breast cancer. Front Oncol. 2020;10: 578963. https://doi.org/10.3389/fonc.2020.578963 .
doi: 10.3389/fonc.2020.578963
pubmed: 33363011
pmcid: 7757663
Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol Cancer. 2019;18(1):127. https://doi.org/10.1186/s12943-019-1053-8 .
doi: 10.1186/s12943-019-1053-8
pubmed: 31438961
pmcid: 6704583
Deng J, Zhang J, Ye Y, et al. N(6)-Methyladenosine-mediated upregulation of WTAPP1 promotes WTAP translation and Wnt signaling to facilitate pancreatic cancer progression. Cancer Res. 2021;81(20):5268–83. https://doi.org/10.1158/0008-5472.Can-21-0494 .
doi: 10.1158/0008-5472.Can-21-0494
pubmed: 34362795
pmcid: 9662857
Zhang J, Tsoi H, Li X, et al. Carbonic anhydrase IV inhibits colon cancer development by inhibiting the Wnt signalling pathway through targeting the WTAP–WT1–TBL1 axis. Gut. 2016;65(9):1482–93. https://doi.org/10.1136/gutjnl-2014-308614 .
doi: 10.1136/gutjnl-2014-308614
pubmed: 26071132
Yu HL, Ma XD, Tong JF, Li JQ, Guan XJ, Yang JH. WTAP is a prognostic marker of high-grade serous ovarian cancer and regulates the progression of ovarian cancer cells. Onco Targets Ther. 2019;12:6191–201. https://doi.org/10.2147/ott.S205730 .
doi: 10.2147/ott.S205730
pubmed: 31496724
pmcid: 6689666
Wang Y, Zhang L, Sun XL, et al. NRP1 contributes to stemness and potentiates radioresistance via WTAP-mediated m6A methylation of Bcl-2 mRNA in breast cancer. Apoptosis. 2023;28(1–2):233–46. https://doi.org/10.1007/s10495-022-01784-3 .
doi: 10.1007/s10495-022-01784-3
pubmed: 36333630
Lv CG, Cheng Y, Zhang L, et al. EXOSC2 mediates the pro-tumor role of WTAP in breast cancer cells via activating the Wnt/β-catenin signal. Mol Biotechnol. 2023. https://doi.org/10.1007/s12033-023-00834-8 .
doi: 10.1007/s12033-023-00834-8
pubmed: 38135832
Melstrom L, Chen J. RNA N(6)-methyladenosine modification in solid tumors: new therapeutic frontiers. Cancer Gene Ther. 2020;27(9):625–33. https://doi.org/10.1038/s41417-020-0160-4 .
doi: 10.1038/s41417-020-0160-4
pubmed: 31956264
pmcid: 8627172
Park SH, Ju JS, Woo H, et al. The m(6)A writer RBM15 drives the growth of triple-negative breast cancer cells through the stimulation of serine and glycine metabolism. Exp Mol Med. 2024. https://doi.org/10.1038/s12276-024-01235-w .
doi: 10.1038/s12276-024-01235-w
pubmed: 39394462
pmcid: 11447051
Wang T, Bai J, Zhang Y, Xue Y, Peng Q. N(6)-Methyladenosine regulator RBM15B acts as an independent prognostic biomarker and its clinical significance in uveal melanoma. Front Immunol. 2022;13: 918522. https://doi.org/10.3389/fimmu.2022.918522 .
doi: 10.3389/fimmu.2022.918522
pubmed: 36003405
pmcid: 9393712
Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103. https://doi.org/10.1186/s12943-019-1033-z .
doi: 10.1186/s12943-019-1033-z
pubmed: 31142332
pmcid: 6540575
Li N, Zhu Z, Deng Y, et al. KIAA1429/VIRMA promotes breast cancer progression by m(6) A-dependent cytosolic HAS2 stabilization. EMBO Rep. 2023;24(10): e55506. https://doi.org/10.15252/embr.202255506 .
doi: 10.15252/embr.202255506
pubmed: 37705505
pmcid: 10561361
Qian JY, Gao J, Sun X, et al. KIAA1429 acts as an oncogenic factor in breast cancer by regulating CDK1 in an N6-methyladenosine-independent manner. Oncogene. 2019;38(33):6123–41. https://doi.org/10.1038/s41388-019-0861-z .
doi: 10.1038/s41388-019-0861-z
pubmed: 31285549
Zhang X, Dai XY, Qian JY, et al. SMC1A regulated by KIAA1429 in m6A-independent manner promotes EMT progress in breast cancer. Mol Ther Nucleic Acids. 2022;27:133–46. https://doi.org/10.1016/j.omtn.2021.08.009 .
doi: 10.1016/j.omtn.2021.08.009
pubmed: 34976433
Wang T, Kong S, Tao M, Ju S. The potential role of RNA N6-methyladenosine in cancer progression. Mol Cancer. 2020;19(1):88. https://doi.org/10.1186/s12943-020-01204-7 .
doi: 10.1186/s12943-020-01204-7
pubmed: 32398132
pmcid: 7216508
Funakoshi Y, Wang Y, Semba T, et al. Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype. PLoS ONE. 2019;14(9): e0222336. https://doi.org/10.1371/journal.pone.0222336 .
doi: 10.1371/journal.pone.0222336
pubmed: 31532791
pmcid: 6750603
Li Z, Weng H, Su R, et al. FTO plays an oncogenic role in acute myeloid leukemia as a N(6)-methyladenosine RNA demethylase. Cancer Cell. 2017;31(1):127–41. https://doi.org/10.1016/j.ccell.2016.11.017 .
doi: 10.1016/j.ccell.2016.11.017
pubmed: 28017614
Deng X, Su R, Stanford S, Chen J. Critical enzymatic functions of FTO in obesity and cancer. Front Endocrinol. 2018;9:396. https://doi.org/10.3389/fendo.2018.00396 .
doi: 10.3389/fendo.2018.00396
Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer. Cancer Commun. 2020;40(10):484–500. https://doi.org/10.1002/cac2.12075 .
doi: 10.1002/cac2.12075
Wang S, Zou X, Chen Y, Cho WC, Zhou X. Effect of N6-methyladenosine regulators on progression and prognosis of triple-negative breast cancer. Front Genet. 2020;11: 580036. https://doi.org/10.3389/fgene.2020.580036 .
doi: 10.3389/fgene.2020.580036
pubmed: 33584787
Niu Y, Lin Z, Wan A, et al. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3. Mol Cancer. 2019;18(1):46. https://doi.org/10.1186/s12943-019-1004-4 .
doi: 10.1186/s12943-019-1004-4
pubmed: 30922314
pmcid: 6437932
Ou B, Liu Y, Gao Z, et al. Senescent neutrophils-derived exosomal piRNA-17560 promotes chemoresistance and EMT of breast cancer via FTO-mediated m6A demethylation. Cell Death Dis. 2022;13(10):905. https://doi.org/10.1038/s41419-022-05317-3 .
doi: 10.1038/s41419-022-05317-3
pubmed: 36302751
pmcid: 9613690
Zhang S, Zhao BS, Zhou A, et al. m(6)A demethylase ALKBH5 maintains tumorigenicity of glioblastoma stem-like cells by sustaining FOXM1 expression and cell proliferation program. Cancer Cell. 2017;31(4):591-606.e6. https://doi.org/10.1016/j.ccell.2017.02.013 .
doi: 10.1016/j.ccell.2017.02.013
pubmed: 28344040
pmcid: 5427719
Wang J, Li Y, Wang P, et al. Leukemogenic chromatin alterations promote AML leukemia stem cells via a KDM4C–ALKBH5–AXL signaling axis. Cell Stem Cell. 2020;27(1):81-97.e8. https://doi.org/10.1016/j.stem.2020.04.001 .
doi: 10.1016/j.stem.2020.04.001
pubmed: 32402251
Wang YJ, Yang B, Lai Q, et al. Reprogramming of m(6)A epitranscriptome is crucial for shaping of transcriptome and proteome in response to hypoxia. RNA Biol. 2021;18(1):131–43. https://doi.org/10.1080/15476286.2020.1804697 .
doi: 10.1080/15476286.2020.1804697
pubmed: 32746693
Zhang C, Samanta D, Lu H, et al. Hypoxia induces the breast cancer stem cell phenotype by HIF-dependent and ALKBH5-mediated m
doi: 10.1073/pnas.1602883113
pubmed: 27001847
pmcid: 4833258
Liu H, Lyu H, Jiang G, et al. ALKBH5-mediated m6A demethylation of GLUT4 mRNA promotes glycolysis and resistance to HER2-targeted therapy in breast cancer. Cancer Res. 2022;82(21):3974–86. https://doi.org/10.1158/0008-5472.Can-22-0800 .
doi: 10.1158/0008-5472.Can-22-0800
pubmed: 36069931
Liu X, Li P, Huang Y, et al. M(6)A demethylase ALKBH5 regulates FOXO1 mRNA stability and chemoresistance in triple-negative breast cancer. Redox Biol. 2024;69: 102993. https://doi.org/10.1016/j.redox.2023.102993 .
doi: 10.1016/j.redox.2023.102993
pubmed: 38104484
Anita R, Paramasivam A, Priyadharsini JV, Chitra S. The m6A readers YTHDF1 and YTHDF3 aberrations associated with metastasis and predict poor prognosis in breast cancer patients. Am J Cancer Res. 2020;10(8):2546–54.
pubmed: 32905518
pmcid: 7471347
Liu T, Wei Q, Jin J, et al. The m6A reader YTHDF1 promotes ovarian cancer progression via augmenting EIF3C translation. Nucleic Acids Res. 2020;48(7):3816–31. https://doi.org/10.1093/nar/gkaa048 .
doi: 10.1093/nar/gkaa048
pubmed: 31996915
pmcid: 7144925
Bai Y, Yang C, Wu R, et al. YTHDF1 regulates tumorigenicity and cancer stem cell-like activity in human colorectal carcinoma. Front Oncol. 2019;9:332. https://doi.org/10.3389/fonc.2019.00332 .
doi: 10.3389/fonc.2019.00332
pubmed: 31131257
pmcid: 6509179
Shi Y, Fan S, Wu M, et al. YTHDF1 links hypoxia adaptation and non-small cell lung cancer progression. Nat Commun. 2019;10(1):4892. https://doi.org/10.1038/s41467-019-12801-6 .
doi: 10.1038/s41467-019-12801-6
pubmed: 31653849
pmcid: 6814821
Pi J, Wang W, Ji M, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7. Can Res. 2021;81(10):2651–65. https://doi.org/10.1158/0008-5472.Can-20-0066 .
doi: 10.1158/0008-5472.Can-20-0066
Yao X, Li W, Li L, et al. YTHDF1 upregulation mediates hypoxia-dependent breast cancer growth and metastasis through regulating PKM2 to affect glycolysis. Cell Death Dis. 2022;13(3):258. https://doi.org/10.1038/s41419-022-04711-1 .
doi: 10.1038/s41419-022-04711-1
pubmed: 35319018
pmcid: 8940925
Sun Y, Dong D, Xia Y, Hao L, Wang W, Zhao C. YTHDF1 promotes breast cancer cell growth, DNA damage repair and chemoresistance. Cell Death Dis. 2022;13(3):230. https://doi.org/10.1038/s41419-022-04672-5 .
doi: 10.1038/s41419-022-04672-5
pubmed: 35279688
pmcid: 8918344
Hu Y, Pan Q, Wang M, et al. m(6)A RNA methylation regulator YTHDF1 correlated with immune microenvironment predicts clinical outcomes and therapeutic efficacy in breast cancer. Front Med. 2021;8: 667543. https://doi.org/10.3389/fmed.2021.667543 .
doi: 10.3389/fmed.2021.667543
Yin H, Zhang X, Yang P, et al. RNA m6A methylation orchestrates cancer growth and metastasis via macrophage reprogramming. Nat Commun. 2021;12(1):1394. https://doi.org/10.1038/s41467-021-21514-8 .
doi: 10.1038/s41467-021-21514-8
pubmed: 33654093
pmcid: 7925544
Li Y, Wang NX, Yin C, Jiang SS, Li JC, Yang SY. RNA editing enzyme ADAR1 regulates METTL3 in an editing dependent manner to promote breast cancer progression via METTL3/ARHGAP5/YTHDF1 axis. Int J Mol Sci. 2022;23(17):9656. https://doi.org/10.3390/ijms23179656 .
doi: 10.3390/ijms23179656
pubmed: 36077054
pmcid: 9456332
Chen H, Yu Y, Yang M, et al. YTHDF1 promotes breast cancer progression by facilitating FOXM1 translation in an m6A-dependent manner. Cell Biosci. 2022;12(1):19. https://doi.org/10.1186/s13578-022-00759-w .
doi: 10.1186/s13578-022-00759-w
pubmed: 35197112
pmcid: 8867832
Chen YG, Chen R, Ahmad S, et al. N6-Methyladenosine modification controls circular RNA immunity. Mol Cell. 2019;76(1):96-109.e9. https://doi.org/10.1016/j.molcel.2019.07.016 .
doi: 10.1016/j.molcel.2019.07.016
pubmed: 31474572
pmcid: 6778039
Dai XY, Shi L, Li Z, Yang HY, Wei JF, Ding Q. Main N6-methyladenosine readers: YTH family proteins in cancers. Front Oncol. 2021;11: 635329. https://doi.org/10.3389/fonc.2021.635329 .
doi: 10.3389/fonc.2021.635329
pubmed: 33928028
pmcid: 8076607
Einstein JM, Perelis M, Chaim IA, et al. Inhibition of YTHDF2 triggers proteotoxic cell death in MYC-driven breast cancer. Mol Cell. 2021;81(15):3048-3064.e9. https://doi.org/10.1016/j.molcel.2021.06.014 .
doi: 10.1016/j.molcel.2021.06.014
pubmed: 34216543
pmcid: 8359670
Sui L, Sanders A, Jiang WG, Ye L. Deregulated molecules and pathways in the predisposition and dissemination of breast cancer cells to bone. Comput Struct Biotechnol J. 2022;20:2745–58. https://doi.org/10.1016/j.csbj.2022.05.051 .
doi: 10.1016/j.csbj.2022.05.051
pubmed: 35685372
pmcid: 9168524
Liu X, Yuan J, Zhang X, et al. ATF3 modulates the resistance of breast cancer cells to tamoxifen through an N(6)-methyladenosine-based epitranscriptomic mechanism. Chem Res Toxicol. 2021;34(7):1814–21. https://doi.org/10.1021/acs.chemrestox.1c00206 .
doi: 10.1021/acs.chemrestox.1c00206
pubmed: 34213887
pmcid: 8756675
Li X, Zhang K, Hu Y, Luo N. YTHDF2 regulates cell growth and cycle by facilitating KDM1A mRNA stability. Am J Pathol. 2023;193(4):442–55. https://doi.org/10.1016/j.ajpath.2022.12.010 .
doi: 10.1016/j.ajpath.2022.12.010
pubmed: 36681189
Lv W, Tan Y, Xiong M, et al. Analysis and validation of m6A regulatory network: a novel circBACH2/has-miR-944/HNRNPC axis in breast cancer progression. J Transl Med. 2021;19(1):527. https://doi.org/10.1186/s12967-021-03196-4 .
doi: 10.1186/s12967-021-03196-4
pubmed: 34952600
pmcid: 8709995
Zhao G, An J, Pu Q, et al. Gene signatures and cancer-immune phenotypes based on m(6)A regulators in breast cancer. Front Oncol. 2021;11: 756412. https://doi.org/10.3389/fonc.2021.756412 .
doi: 10.3389/fonc.2021.756412
pubmed: 34804948
pmcid: 8600443
Liu J, Zhu J, Wang X, Zhou Z, Liu H, Zhu D. A novel YTHDF3-based model to predict prognosis and therapeutic response in breast cancer. Front Mol Biosci. 2022;9: 874532. https://doi.org/10.3389/fmolb.2022.874532 .
doi: 10.3389/fmolb.2022.874532
pubmed: 35755811
pmcid: 9218665
Lin Y, Jin X, Nie Q, et al. YTHDF3 facilitates triple-negative breast cancer progression and metastasis by stabilizing ZEB1 mRNA in an m(6)A-dependent manner. Ann Transl Med. 2022;10(2):83. https://doi.org/10.21037/atm-21-6857 .
doi: 10.21037/atm-21-6857
pubmed: 35282088
pmcid: 8848410
Akhtar J, Renaud Y, Albrecht S, et al. m(6)A RNA methylation regulates promoter-proximal pausing of RNA polymerase II. Mol Cell. 2021;81(16):3356-3367.e6. https://doi.org/10.1016/j.molcel.2021.06.023 .
doi: 10.1016/j.molcel.2021.06.023
pubmed: 34297910
Porman AM, Roberts JT, Duncan ED, et al. A single N6-methyladenosine site regulates lncRNA HOTAIR function in breast cancer cells. PLoS Biol. 2022;20(11): e3001885. https://doi.org/10.1371/journal.pbio.3001885 .
doi: 10.1371/journal.pbio.3001885
pubmed: 36441764
pmcid: 9731500
Shen X, Zhong J, Yu P, Liu F, Peng H, Chen N. YTHDC1-dependent m6A modification modulated FOXM1 promotes glycolysis and tumor progression through CENPA in triple-negative breast cancer. Cancer Sci. 2024;115(6):1881–95. https://doi.org/10.1111/cas.16137 .
doi: 10.1111/cas.16137
pubmed: 38566554
pmcid: 11145146
Tan B, Zhou K, Liu W, et al. RNA N(6)-methyladenosine reader YTHDC1 is essential for TGF-beta-mediated metastasis of triple negative breast cancer. Theranostics. 2022;12(13):5727–43. https://doi.org/10.7150/thno.71872 .
doi: 10.7150/thno.71872
pubmed: 35966596
pmcid: 9373808
Yang L, Wu S, Ma C, et al. RNA m(6)A methylation regulators subclassify luminal subtype in breast cancer. Front Oncol. 2020;10: 611191. https://doi.org/10.3389/fonc.2020.611191 .
doi: 10.3389/fonc.2020.611191
pubmed: 33585234
Bando Y, Kobayashi T, Miyakami Y, et al. Triple-negative breast cancer and basal-like subtype: pathology and targeted therapy. J Med Investig. 2021;68(3.4):213–9. https://doi.org/10.2152/jmi.68.213 .
doi: 10.2152/jmi.68.213
Zhu TY, Hong LL, Ling ZQ. Oncofetal protein IGF2BPs in human cancer: functions, mechanisms and therapeutic potential. Biomark Res. 2023;11(1):62. https://doi.org/10.1186/s40364-023-00499-0 .
doi: 10.1186/s40364-023-00499-0
pubmed: 37280679
pmcid: 10245617
Ying Y, Ma X, Fang J, et al. EGR2-mediated regulation of m(6)A reader IGF2BP proteins drive RCC tumorigenesis and metastasis via enhancing S1PR3 mRNA stabilization. Cell Death Dis. 2021;12(8):750. https://doi.org/10.1038/s41419-021-04038-3 .
doi: 10.1038/s41419-021-04038-3
pubmed: 34326314
pmcid: 8322060
Wu S, Yun J, Tang W, et al. Therapeutic m(6)A eraser ALKBH5 mRNA-loaded exosome-liposome hybrid nanoparticles inhibit progression of colorectal cancer in preclinical tumor models. ACS Nano. 2023;17(12):11838–54. https://doi.org/10.1021/acsnano.3c03050 .
doi: 10.1021/acsnano.3c03050
pubmed: 37310898
Jiang T, He X, Zhao Z, Zhang X, Wang T, Jia L. RNA m6A reader IGF2BP3 promotes metastasis of triple-negative breast cancer via SLIT2 repression. Faseb J. 2022;36(11): e22618. https://doi.org/10.1096/fj.202200751RR .
doi: 10.1096/fj.202200751RR
pubmed: 36250924
Chen D, Zang L, Zhou Y, et al. IGF2BP2-related modification patterns in pancreatic cancer: a machine learning-driven approach towards personalized treatment. Heliyon. 2024;10(6): e28243. https://doi.org/10.1016/j.heliyon.2024.e28243 .
doi: 10.1016/j.heliyon.2024.e28243
pubmed: 38545193
pmcid: 10965819
Huang X, Zhang H, Guo X, Zhu Z, Cai H, Kong X. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) in cancer. J Hematol Oncol. 2018;11(1):88. https://doi.org/10.1186/s13045-018-0628-y .
doi: 10.1186/s13045-018-0628-y
pubmed: 29954406
pmcid: 6025799
Wang J, Chen L, Qiang P. The role of IGF2BP2, an m6A reader gene, in human metabolic diseases and cancers. Cancer Cell Int. 2021;21(1):99. https://doi.org/10.1186/s12935-021-01799-x .
doi: 10.1186/s12935-021-01799-x
pubmed: 33568150
pmcid: 7876817
Peng F, Xu J, Cui B, et al. Oncogenic AURKA-enhanced N(6)-methyladenosine modification increases DROSHA mRNA stability to transactivate STC1 in breast cancer stem-like cells. Cell Res. 2021;31(3):345–61. https://doi.org/10.1038/s41422-020-00397-2 .
doi: 10.1038/s41422-020-00397-2
pubmed: 32859993
Liu X, Chen J, Chen W, Xu Y, Shen Y, Xu X. Targeting IGF2BP3 in cancer. Int J Mol Sci. 2023;24(11):9423. https://doi.org/10.3390/ijms24119423 .
doi: 10.3390/ijms24119423
pubmed: 37298373
pmcid: 10253605
Bao G, Huang J, Pan W, Li X, Zhou T. Long noncoding RNA CERS6-AS1 functions as a malignancy promoter in breast cancer by binding to IGF2BP3 to enhance the stability of CERS6 mRNA. Cancer Med. 2020;9(1):278–89. https://doi.org/10.1002/cam4.2675 .
doi: 10.1002/cam4.2675
pubmed: 31701672
Bi Z, Liu Y, Zhao Y, et al. A dynamic reversible RNA N(6)-methyladenosine modification: current status and perspectives. J Cell Physiol. 2019;234(6):7948–56. https://doi.org/10.1002/jcp.28014 .
doi: 10.1002/jcp.28014
pubmed: 30644095
Singh R, Gupta SC, Peng WX, et al. Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis. Cell Death Dis. 2016;7(6): e2262. https://doi.org/10.1038/cddis.2016.168 .
doi: 10.1038/cddis.2016.168
pubmed: 27277684
pmcid: 5143396
Sudhakaran M, Parra MR, Stoub H, Gallo KA, Doseff AI. Apigenin by targeting hnRNPA2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters. Biochem Pharmacol. 2020;182: 114259. https://doi.org/10.1016/j.bcp.2020.114259 .
doi: 10.1016/j.bcp.2020.114259
pubmed: 33011162
pmcid: 8020486
Wu Y, Zhao W, Liu Y, et al. Function of HNRNPC in breast cancer cells by controlling the dsRNA-induced interferon response. EMBO J. 2018;37(23): e99017. https://doi.org/10.15252/embj.201899017 .
doi: 10.15252/embj.201899017
pubmed: 30158112
pmcid: 6276880
Sarbanes SL, Le Pen J, Rice CM. Friend and foe, HNRNPC takes on immunostimulatory RNAs in breast cancer cells. EMBO J. 2018;37(23): e100923. https://doi.org/10.15252/embj.2018100923 .
doi: 10.15252/embj.2018100923
pubmed: 30389667
pmcid: 6276875
Lian B, Yan S, Li J, Bai Z, Li J. HNRNPC promotes collagen fiber alignment and immune evasion in breast cancer via activation of the VIRMA-mediated TFAP2A/DDR1 axis. Mol Med. 2023;29(1):103. https://doi.org/10.1186/s10020-023-00696-5 .
doi: 10.1186/s10020-023-00696-5
pubmed: 37528369
pmcid: 10394847
Zhang C, Guo C, Li Y, Ouyang L, Zhao Q, Liu K. The role of YTH domain containing 2 in epigenetic modification and immune infiltration of pan-cancer. J Cell Mol Med. 2021;25(18):8615–27. https://doi.org/10.1111/jcmm.16818 .
doi: 10.1111/jcmm.16818
pubmed: 34312987
pmcid: 8435423
Yin J, Gu T, Chaudhry N, Davidson NE, Huang Y. Epigenetic modulation of antitumor immunity and immunotherapy response in breast cancer: biological mechanisms and clinical implications. Front Immunol. 2023;14:1325615. https://doi.org/10.3389/fimmu.2023.1325615 .
doi: 10.3389/fimmu.2023.1325615
pubmed: 38268926